HPV prevalence around the time of sexual debut in adolescent girls in Tanzania

Objectives Cervical cancer is the leading cause of cancer-related mortality among women in sub-Saharan Africa (SSA). Data on human papillomavirus (HPV) epidemiology in adolescent girls in SSA are essential to inform HPV vaccine policy recommendations for cervical cancer prevention. We assessed the burden of HPV infection, and risk factors for infection, among adolescent girls around the time of sexual debut. Methods Cross-sectional study of secondary school girls aged 17–18 years in Tanzania. Consenting participants provided samples for HPV and STI testing. Vaginal swabs were tested for 37 HPV genotypes by Roche Linear Array. Logistic regression was used to identify factors associated with HPV infection. Y chromosome was tested as a marker of recent condomless sex. Results 163/385 girls (42.3%) reported previous penetrative sex. HPV was detected in 125/385 (32.5%) girls, including 84/163 (51.5%) girls reporting previous sex and 41/222 (18.5%) reporting no previous sex. High-risk (HR) genotypes were detected in 70/125 (56.0%) girls with HPV infection. The most common HR genotype was HPV-16 (15/385; 3.9%). The prevalence of other HR HPV vaccine genotypes was between 0.8% and 3.1%. Among 186 girls who reported no previous sex, were negative for Y chromosome, and had no STI, 32 (17%) had detectable HPV. Lactobacillus sp and bacterial vaginosis-associated bacteria were negatively and positively associated, respectively, with HPV. Conclusions HPV prevalence among adolescent girls around the time of sexual debut was high. However, prevalence of most vaccine genotypes was low, indicating that extending the age range of HPV vaccination in this region may be cost-effective.

[1]  J. H. van de Wijgert,et al.  Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. , 2019, American journal of obstetrics and gynecology.

[2]  R. Hayes,et al.  Human papillomavirus DNA detected in fingertip, oral and bathroom samples from unvaccinated adolescent girls in Tanzania , 2019, Sexually Transmitted Infections.

[3]  J. Ravel,et al.  The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Suzanna C. Francis,et al.  Results from a cross-sectional sexual and reproductive health study among school girls in Tanzania: high prevalence of bacterial vaginosis , 2018, Sexually Transmitted Infections.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  T. Ramqvist,et al.  Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique , 2017, BMJ Open.

[7]  D. Harper,et al.  HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.

[8]  R. Hayes,et al.  The Incidence of Human Papillomavirus in Tanzanian Adolescent Girls Before Reported Sexual Debut , 2016, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[9]  Suzanna C. Francis,et al.  The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization? , 2014, PloS one.

[10]  R. Hayes,et al.  Prevalence of Human Papillomavirus in Adolescent Girls Before Reported Sexual Debut , 2014, Journal of Infectious Diseases.

[11]  C. Kenyon,et al.  The global epidemiology of bacterial vaginosis: a systematic review. , 2013, American journal of obstetrics and gynecology.

[12]  G. Doncel,et al.  TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies. , 2013, Contraception.

[13]  Joelle M. Brown,et al.  High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects , 2013, Sexually Transmitted Infections.

[14]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[15]  R. Hayes,et al.  Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis , 2012, AIDS.

[16]  C. Wheeler,et al.  Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 , 2012, International journal of cancer.

[17]  J. Menten,et al.  Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests , 2012, BMC Microbiology.

[18]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[19]  E. Weiderpass,et al.  Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda , 2010, Infectious Agents and Cancer.

[20]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[21]  S. de Sanjosé,et al.  The Epidemiology of Human Papillomavirus Infection and Cervical Cancer , 2007, Disease markers.

[22]  F. X. Bosch,et al.  CHAPTER 2 The epidemiology of human papillomavirus infection and its association with cervical cancer , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  A. Burchell,et al.  Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. , 2006, Vaccine.

[24]  M. Schiffman,et al.  Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.

[25]  J. Fortenberry,et al.  A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.

[26]  A. Giuliano,et al.  Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.

[27]  M. Evander,et al.  The absence of vaginal human papillomavirus 16 DNA in women who have not experienced sexual intercourse , 1994, Obstetrics and gynecology.

[28]  Children,et al.  Tanzania demographic and health survey and malaria indicator survey 2015-2016: final report/ Tanzania, Ofisi ya Taifa ya Takwimu , 2016 .

[29]  N. Kiviat,et al.  Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students , 2003 .